PRKDC and cancer: DNA-PKcs inhibitors have been shown to be essential in several cancers and these inhibitors alone have been shown to strongly affect the survival of cancer cells of different lineages [67,68,69] despite ambivalent responses [50,67], highlighting the need for biomarkers to improve the clinical utility of DNA-PKcs-targeted therapy.